Archer Materials (ASX: AXE) reported meaningful technical progress across its quantum computing and medical diagnostics platforms during the December 2025 quarter. Archer also strengthened its commercial pathway through new collaborations with Emergence Quantum and CSIRO, extending its reach into next-generation quantum devices and quantum-enhanced machine learning. Biochip Development MilestoneThe Biochip program delivered a significant result after silicon-based devices demonstrated blood potassium measurement accuracy that met clinical standards. Archer said Mr Just brings extensive global experience in scaling health and medical technology businesses, strengthening the board as the Biochip program progresses. Archer remains well-funded with no debt, as it continues to advance both its quantum computing and medical diagnostics platforms.